NCT06800729View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Healthy

Interventions

DRUG

TIX100, an orally available inhibitor of thioredoxin-interacting protein

TIX100, an orally available inhibitor of thioredoxin-interacting protein

DRUG

Placebo

placebo

Trial Locations (1)

91911

RECRUITING

ProSciento, Inc., Chula Vista

All Listed Sponsors

lead

TIXiMED, Inc.

INDUSTRY